MIRA Pharmaceuticals, Inc. (MIRA) Stock Forecast & Price Target

MIRA Pharmaceuticals, Inc. (MIRA) has an ST Score of 35.5 (C-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Analysts rate MIRA a Buy. Our ST Score grades it C- (35.5/100). The ST Score is a data-driven signal, not a recommendation.

Valuation A-, Profitability F, Financial Strength A-, Momentum D, Growth D+.

MIRA Pharmaceuticals, Inc. (MIRA) earns a valuation grade of A-, measured against Drug Manufacturers - General peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

MIRA Pharmaceuticals, Inc. (MIRA) earns a growth grade of D+, measured against Drug Manufacturers - General peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

MIRA Pharmaceuticals, Inc. (MIRA) earns a profitability grade of F, measured against Drug Manufacturers - General peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

MIRA Pharmaceuticals, Inc. (MIRA) earns a financial strength grade of A-, measured against Drug Manufacturers - General peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

MIRA Pharmaceuticals, Inc. (MIRA) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.